Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends drug to treat heart failure

  • Comment

People with heart failure could soon benefit from using Procoralan after it was recommended for use by the National Institute for Clinical Excellence (NICE).

NICE said the drug, which contains ivabradine, has been shown to have beneficial effect in reducing mortality and improving the quality of life for patients.

Around 900,000 people in the UK are affected by heart failure, and data on Procoralan suggests it could cut death rates and the need for a patient to be taken to hospital with the condition.

NICE stated the drug could be considered as a treatment option if patients are still symptomatic after receiving optimised initial therapies, or when patients do not tolerate beta-blockers.

Professor Carole Longson, NICE director, said the prevalence of heart failure is expected to rise in the future as a greater number of people live longer, so it is therefore necessary to make use of better treatments for the condition.

She added the committee concluded that ivabradine could be considered a “cost-effective” use of NHS resources for treating chronic heart failure.

Procoralan costs about £10 a week and is already prescribed for patients in the UK with angina.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.